The Severe Asthma Questionnaire: sensitivity to change and minimal clinically important difference

Matthew Masoli; Joseph W. Lanario; Michael E. Hyland; Andrew Menzies-Gow; Adel H. Mansur; David Allen; James W. Dodd; Gemma Hayes; Jose M. Valderas; Sarah E. Lamb; Rupert C. Jones

doi:10.1183/13993003.00300-2021

The Severe Asthma Questionnaire: sensitivity to change and minimal clinically important difference

Matthew Masoli, Joseph W. Lanario, Michael E. Hyland, Andrew Menzies-Gow, Adel H. Mansur, David Allen, James W. Dodd, Gemma Hayes, Jose M. Valderas, Sarah E. Lamb, Rupert C. Jones

Research output: Contribution to journal › Article (Academic Journal) › peer-review

7 Citations (Scopus)

52 Downloads (Pure)

Original language	English
Article number	2100300
Journal	European Respiratory Journal
Volume	57
Issue number	6
DOIs	https://doi.org/10.1183/13993003.00300-2021
Publication status	Published - 25 Jun 2021

Bibliographical note

Funding Information:
from the Research Ethics Committee/Health Research Authority (REC reference: 19/WA/0011, IRAS project ID: 250167) and was sponsored by University Hospitals Plymouth NHS Trust.

Funding Information:
during the conduct of the study. J.W. Lanario reports grants from GSK, during the conduct of the study; personal fees from Novartis, outside the submitted work. M.E. Hyland reports grants from GSK, during the conduct of the study; personal fees from GSK, outside the submitted work. A. Menzies-Gow reports grants and personal fees from AstraZeneca, personal fees and non-financial support from Teva, and personal fees from Novartis, GlaxoSmithKline, Sanofi, Roche and Vectura, outside the submitted work. A.H. Mansur reports grants, personal fees, non-financial support and other (for various activities that include talks, advisory board meeting, sponsorship for conferences) from NAPP, Cheisi, AstraZeneca, GSK, Sanofi, Teva, outside the submitted work. D. Allen reports personal fees (advisory boards) from AstraZeneca and GSK, personal fees and non-financial support from Teva (speaker fees, and sponsorship support to attend conferences), outside the submitted work. J.W. Dodd has nothing to disclose. G. Hayes has nothing to disclose. J.M. Valderas has nothing to disclose. S.E Lamb was on the Health Technology Assessment (HTA) Additional Capacity Funding Board, HTA End of Life Care and Add-on Studies Board, HTA Prioritisation Group Board and the HTA Trauma Board. R.C. Jones reports grants from GlaxoSmithKline, during the conduct of the study; grants, personal fees and non-financial support from AstraZeneca and GlaxoSmithKline, personal fees and non-financial support from Boehringer Ingelheim, Novartis, Nutricia and OPRI, outside the submitted work.

Research Groups and Themes

Academic Respiratory Unit

Access to Document

10.1183/13993003.00300-2021Licence: CC BY-NC

Full-text PDF (final published version)
This is the final published version of the article (version of record). It first appeared online via ERS at https://doi.org/10.1183/13993003.00300-2021. Please refer to any applicable terms of use of the publisher.
Final published version, 423 KBLicence: CC BY-NC

Handle.net

Persistent link

Cite this

@article{c56c20c06c854c92a1dac879dcb1516c,

title = "The Severe Asthma Questionnaire: sensitivity to change and minimal clinically important difference",

author = "Matthew Masoli and Lanario, {Joseph W.} and Hyland, {Michael E.} and Andrew Menzies-Gow and Mansur, {Adel H.} and David Allen and Dodd, {James W.} and Gemma Hayes and Valderas, {Jose M.} and Lamb, {Sarah E.} and Jones, {Rupert C.}",

note = "Funding Information: from the Research Ethics Committee/Health Research Authority (REC reference: 19/WA/0011, IRAS project ID: 250167) and was sponsored by University Hospitals Plymouth NHS Trust. Funding Information: during the conduct of the study. J.W. Lanario reports grants from GSK, during the conduct of the study; personal fees from Novartis, outside the submitted work. M.E. Hyland reports grants from GSK, during the conduct of the study; personal fees from GSK, outside the submitted work. A. Menzies-Gow reports grants and personal fees from AstraZeneca, personal fees and non-financial support from Teva, and personal fees from Novartis, GlaxoSmithKline, Sanofi, Roche and Vectura, outside the submitted work. A.H. Mansur reports grants, personal fees, non-financial support and other (for various activities that include talks, advisory board meeting, sponsorship for conferences) from NAPP, Cheisi, AstraZeneca, GSK, Sanofi, Teva, outside the submitted work. D. Allen reports personal fees (advisory boards) from AstraZeneca and GSK, personal fees and non-financial support from Teva (speaker fees, and sponsorship support to attend conferences), outside the submitted work. J.W. Dodd has nothing to disclose. G. Hayes has nothing to disclose. J.M. Valderas has nothing to disclose. S.E Lamb was on the Health Technology Assessment (HTA) Additional Capacity Funding Board, HTA End of Life Care and Add-on Studies Board, HTA Prioritisation Group Board and the HTA Trauma Board. R.C. Jones reports grants from GlaxoSmithKline, during the conduct of the study; grants, personal fees and non-financial support from AstraZeneca and GlaxoSmithKline, personal fees and non-financial support from Boehringer Ingelheim, Novartis, Nutricia and OPRI, outside the submitted work.",

year = "2021",

month = jun,

day = "25",

doi = "10.1183/13993003.00300-2021",

language = "English",

volume = "57",

journal = "European Respiratory Journal",

issn = "0903-1936",

publisher = "European Respiratory Society",

number = "6",

}

TY - JOUR

T1 - The Severe Asthma Questionnaire: sensitivity to change and minimal clinically important difference

AU - Masoli, Matthew

AU - Lanario, Joseph W.

AU - Hyland, Michael E.

AU - Menzies-Gow, Andrew

AU - Mansur, Adel H.

AU - Allen, David

AU - Dodd, James W.

AU - Hayes, Gemma

AU - Valderas, Jose M.

AU - Lamb, Sarah E.

AU - Jones, Rupert C.

N1 - Funding Information: from the Research Ethics Committee/Health Research Authority (REC reference: 19/WA/0011, IRAS project ID: 250167) and was sponsored by University Hospitals Plymouth NHS Trust. Funding Information: during the conduct of the study. J.W. Lanario reports grants from GSK, during the conduct of the study; personal fees from Novartis, outside the submitted work. M.E. Hyland reports grants from GSK, during the conduct of the study; personal fees from GSK, outside the submitted work. A. Menzies-Gow reports grants and personal fees from AstraZeneca, personal fees and non-financial support from Teva, and personal fees from Novartis, GlaxoSmithKline, Sanofi, Roche and Vectura, outside the submitted work. A.H. Mansur reports grants, personal fees, non-financial support and other (for various activities that include talks, advisory board meeting, sponsorship for conferences) from NAPP, Cheisi, AstraZeneca, GSK, Sanofi, Teva, outside the submitted work. D. Allen reports personal fees (advisory boards) from AstraZeneca and GSK, personal fees and non-financial support from Teva (speaker fees, and sponsorship support to attend conferences), outside the submitted work. J.W. Dodd has nothing to disclose. G. Hayes has nothing to disclose. J.M. Valderas has nothing to disclose. S.E Lamb was on the Health Technology Assessment (HTA) Additional Capacity Funding Board, HTA End of Life Care and Add-on Studies Board, HTA Prioritisation Group Board and the HTA Trauma Board. R.C. Jones reports grants from GlaxoSmithKline, during the conduct of the study; grants, personal fees and non-financial support from AstraZeneca and GlaxoSmithKline, personal fees and non-financial support from Boehringer Ingelheim, Novartis, Nutricia and OPRI, outside the submitted work.

PY - 2021/6/25

Y1 - 2021/6/25

UR - https://doi.org/10.1183/13993003.00300-2021

U2 - 10.1183/13993003.00300-2021

DO - 10.1183/13993003.00300-2021

M3 - Article (Academic Journal)

C2 - 33632801

SN - 0903-1936

VL - 57

JO - European Respiratory Journal

JF - European Respiratory Journal

IS - 6

M1 - 2100300

ER -

The Severe Asthma Questionnaire: sensitivity to change and minimal clinically important difference

Bibliographical note

Research Groups and Themes

Access to Document

Handle.net

Other files and links

Cite this